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ABSTRACT
Objective To investigate the effect of opiate substitution
treatment at the beginning and end of treatment and
according to duration of treatment.
Design Prospective cohort study.
Setting UK General Practice Research Database
Participants Primary care patients with a diagnosis of
substance misuse prescribed methadone or
buprenorphine during 1990-2005. 5577 patients with
267003 prescriptions for opiate substitution treatment
followed-up (17732 years) until one year after the expiry
of their last prescription, the date of death before this
time had elapsed, or the date of transfer away from the
practice.
Mainoutcome measuresMortality rates and rate ratios
comparing periods in and out of treatment adjusted for
sex, age, calendar year, and comorbidity; standardised
mortality ratios comparing opiate users’mortality with
general population mortality rates.
Results Crude mortality rates were 0.7 per 100 person
years on opiate substitution treatment and 1.3 per 100
person years off treatment; standardised mortality ratios
were 5.3 (95% confidence interval 4.0 to 6.8) on
treatment and 10.9 (9.0 to 13.1) off treatment. Men using
opiates had approximately twice the risk of death of
women (morality rate ratio 2.0, 1.4 to 2.9). In the first two
weeks of opiate substitution treatment the crude
mortality rate was 1.7 per 100 person years: 3.1 (1.5 to
6.6) times higher (after adjustment for sex, age group,
calendar period, and comorbidity) than the rate during the
rest of time on treatment. The crudemortality rate was 4.8
per 100 person years in weeks 1-2 after treatment
stopped, 4.3 in weeks 3-4, and 0.95 during the rest of
time off treatment: 9 (5.4 to 14.9), 8 (4.7 to 13.7), and 1.9
(1.3 to 2.8) times higher than the baseline risk ofmortality
during treatment. Opiate substitution treatment has a
greater than 85% chance of reducing overall mortality
among opiate users if the average duration approaches or
exceeds 12 months.
Conclusions Clinicians and patients should be aware of
the increased mortality risk at the start of opiate
substitution treatment and immediately after stopping
treatment. Further research is needed to investigate the
effect of averageduration of opiate substitution treatment
on drug related mortality.
INTRODUCTION
Opiate users have a high risk of death and contribute
substantially to adult mortality.1 Systematic reviews
estimate annual death rates of about 1%, which is
more than 10 times that of the general population and
contributes more than 10% of adult mortality.2-4 In the
United Kingdom and many other countries, most
deaths among opiate users are due to overdose, and
opiates are the most common cause of poisoning
from controlled drugs in the population.5-8 Estimates
of the prevalence of opiate use in the UK suggest 30-
fold increases between 1970 and 2000,9 but more
recent estimates are stable at around 250 000 opiate
users (approximately 0.8% of adults aged 15-64).10 11
Good evidence shows that opiate substitution treat-
ment, primarily with methadone and buprenorphine,
is effective across a range of outcomes, including redu-
cing all cause mortality, improving physical and men-
tal health, and decreasing illicit drug use, criminal
activity, and risk of HIV infection.12-19 In the UK, opi-
ate substitution treatment is delivered mainly within
primary care, often through shared care arrangements
with specialist drug agencies.20 21 In the past decade,
opiate prescription has more than doubled while the
number of deaths involvingmethadone and police sei-
zures of methadone have declined, coinciding in part
with the introduction and roll-out of greater supervised
consumption of opiate substitution treatment.7 22 How-
ever, the overall number of deaths from overdose of
opiates has not decreased and targets to reduce deaths
from overdose in England and Wales have not been
met, despite an apparently stable population taking
opiates and considerable investment in treatment.8
The risk of death during and after treatment seems to
be non-uniform. Treatment guidelines and recent stu-
dies have suggested that the start of treatment (the first
28 days) may be associated with an increased risk of
death.23-26 Furthermore, findings in two large cohorts
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in Italy andAustralia have suggested that an excess risk
of death exists in the period immediately after treat-
ment ends.24 27We estimated the effect of opiate substi-
tution treatment delivered in UK primary care on all
causemortality, investigated whether risk of death was
elevated in the first few weeks of treatment and in the
period immediately after treatment, and projected the
likely impact of opiate substitution treatment on drug
related mortality for different durations of treatment.
METHODS
The data for this study come from theGeneral Practice
Research Database (www.gprd.com), a large database
of anonymised patients’ records from more than
460 general practices in the UK. It collects data from
3.5 million patients, equivalent to around 5.5% of the
UK’s population. The study cohort consisted of
patients who received at least one prescription for
methadone or buprenorphine between 1 January
1990 and 31 December 2005 and who had a recorded
diagnosis of substance misuse.We excluded patients if
they were aged 60 or over when first prescribed bupre-
norphine or methadone, were prescribed injectable
drugs, or were prescribed opiates specifically for
pain. The prescription records contained details of
each patient’s unique database identification number,
date of prescription, quantity prescribed, duration, and
daily dose. We used each patient’s identification num-
ber to link the prescription records to data on age and
sex as well as to all other prescriptions dispensed to the
patient during follow-up. If the quantity prescribed,
duration, or daily dose was missing, we calculated it
(where possible) from other prescription data. We
defined patients as being “on treatment” until the
expiry date of their last prescription unless they had a
gap of less than 28 days between the expiry of one pre-
scription and the issue date of the next. In such cases,
we defined the patient as being “on treatment” during
this gap.We chose this period because the prescription
data within long term treatment episodes could be
incomplete andwe considered it unlikely that a patient
would genuinely stop and restart treatment in general
practice within a four week period. In addition, we
examined the prescription data for evidence of other
opiate substitution drugs and identified substantial
numbers of patients with prescriptions for oral dihy-
drocodeine at levels prescribed for opiate substitution
treatment, which has a history of use in general prac-
tice. 28 Therefore, we included these dihydrocodeine
prescriptions as opiate substitution treatment. We did
not includepatients prescribedonly dihydrocodeine in
the initial data extraction.
For each treatment episode, we determined whether
the patient received at least one daily dose of metha-
done, buprenorphine, or dihydrocodeine on or above
the recommended maintenance thresholds of 60 mg,
12 mg, and 600 mg.26 28 For patients on methadone or
buprenorphine, we defined “planned discharge” on
the basis of a tapering dose towards the end of the pre-
scribing period with last prescription being for metha-
done 10 mg or less or buprenorphine 4 mg or less. We
calculated a comorbidity score as the total number of
prescriptions for drugs other than opiate substitution
treatment during each year of follow-up; this method
is similar in performance to more complex comorbid-
ity measures that until very recently were unavailable
for the General Practice Research Database.29 30
Statistical analysis
The outcome measure was all cause mortality. A
patient’s follow-up ceased either one year after the
expiry of their last prescription for opiate substitution
treatment, on the date of death before this time had
elapsed, or on the date of transfer away from the prac-
tice (while on opiate substitution treatment or in the
12 month period after treatment). Patients transferred
away or lost to follow-up contributed their exposure on
or off treatment until the date of transfer. Several of the
covariates varied with time. Time on or off treatment,
including whether this was in the first two or four
weeks, was the key exposure; we also divided each
patient’s follow-up into five year age groups and
according to calendar year, treatment episode, and
comorbidity score. We calculated crude mortality
rates by dividing the total number of deaths in a
particular exposure subgroup by the total amount of
follow-up in this group. We used Poisson regression
to estimate mortality rate ratios comparing periods in
and out of treatment, adjusted for potential confoun-
ders (sex, age group, calendar period, comorbidity
score, treatment episode, and episodes with one opiate
substitution treatment at or above recommended
levels for maintenance). We calculated indirect stan-
dardised mortality ratios on the basis of 1998 sex spe-
cific death rates in England andWales for five year age
groups. We used Stata version 10.0 for analyses.
Sensitivity and secondary analyses
We fitted an interaction to test for differences in the risk
of death at different treatment periods betweenmetha-
done and buprenorphine. In addition, we fitted an
interaction to test whether a difference existed in the
risk of death in the first 28 days “off treatment” for
patients with evidence of tapered prescribing before
treatment ceased. We may have misclassified time on
and off treatment (in our attempt to allow for missing
information on prescriptions) and introduced bias—
for example, if occasions existed when patients were
genuinely off treatment during a gap of less than
28 days between prescriptions. Therefore, we did a
sensitivity analysis by restricting the analysis to each
patient’s final treatment episode. We also restricted
the analysis to patients with no prescriptions for oral
dihydrocodeine to test whether the findings were the
same for patients receiving only methadone or bupre-
norphine. Finally, we estimated the probability that
opiate substitution treatment reduces average mortal-
ity for patients exposed to different durations of treat-
ment compared with if they had been unexposed (see
web appendix for methods).
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RESULTS
Sample
The original study cohort included 6252 patients aged
16 to 59 years receiving opiate substitution treatment
with either methadone or buprenorphine (web
appendix fig A). We excluded the following patients:
74 prescribed buprenorphine patches; 19 whose pre-
scriptions specified “for pain;” 152 who received
injectable methadone or buprenorphine; 430 patients
(5983 prescriptions) with insufficient data on dura-
tion, quantity, and daily dose to calculate periods on
and off treatment. This left 5577 (89%) patients with
231 272 prescriptions for methadone or buprenor-
phine. We added 35 731 prescriptions for oral dihy-
drocodeine prescriptions, making a final total of
267 003 prescriptions.
Table 1 shows the characteristics of the sample.More
than half of the patients were prescribed only metha-
done, 8% were prescribed only buprenorphine, and
35% received a combination of different opiate substitu-
tion treatments (including dihydrocodeine). The med-
ian length of follow-up was 2.0 years, and patients
contributed a total of 17732 person years of follow-up:
8940 person years on treatment and 8792 off treatment.
Between 1990 and 2005, 1647 (30%) patients trans-
ferred out of their practices: 743 during opiate substitu-
tion treatment and 904 in the 12months after treatment
(8% and 10% of the person years of follow-up). Patients
who transferred out during the study were more likely
to be women (34% v 29%), to be younger (65% v 55%
aged under 30), and to have less comorbidity (58% v
63% with lowest comorbid score).
More than half of the patients were aged under 30 at
the start of treatment, and 3867 (69%) were men.
Altogether, 13 593 treatment episodes occurred (a
median of two per patient), with a median duration of
70 days (2.3 months) and a mean duration of 240 days
(7.9 months); 36% (2033) of patients had at least one
treatment episode lasting 12 months or more; and the
mean length of treatment episode was longer for
methadone than for buprenorphine (245 v 181 days,
P<0.001, unpaired t test). Daily dose was available for
13 118 (97%) of the 13 593 treatment episodes; of these,
3261 (24%) episodes included at least one daily dose
above the recommended maintenance threshold. A
tapered dose at the end of the prescribed period was
recorded for 10% of methadone episodes and 46% of
buprenorphine episodes.
Effect of opiate substitution treatment on mortality
A total of 178 (3%) patients died either on treatment or
within a year of their last prescription; of these, 62
(35%) died while on treatment. The crude mortality
rate off treatment was almost double that on treatment
(1.3 v 0.7 per 100 person years), and after adjustment
(for age, sex, calendar period, and comorbidity) the
mortality rate ratio was more than twice as high (2.3,
95% confidence interval 1.7 to 3.1). The standardised
mortality ratio comparing death rates among study
patients with the population of England and Wales
was 5.3 (4.0 to 6.8) while on treatment and 10.9 (9.0
to 13.1) off treatment. As mortality in young adults is
generally almost twice as high among men as in
women (mortality rate ratio 2.0, 1.4 to 2.9) (table 2),
the standardised mortality ratio was similar for men
and women (5.0 and 6.4 on treatment and 11.0 and
10.4 off treatment).
Table 2 shows the main findings. Mortality
increased with age and was positively associated with
comorbidity score.Mortality was lower in 2005-6 than
in 1990-4, although after adjustment insufficient evi-
dence existed to suggest that mortality had declined
over time. Mortality was unrelated to treatment
Table 1 | Characteristics of patients and treatment episodes
Characteristics No (%)*
Patients (n=5577)
Male sex 3867 (69)
Age (years) at start of treatment:
<20 260 (5)
20-29 2950 (53)
30-39 1784 (32)
40-49 471 (8)
≥50 112 (2)
Total length of time on treatment:
Median 281 days
Range 1 day to 15.9 years
Mean (SD) 585 (787) days
Treatment received:
Methadone only 3159 (57)
Buprenorphine only 456 (8)
Methadone and buprenorphine 482 (9)
Methadone and dihydrocodeine 1045 (19)
Buprenorphine and dihydrocodeine 227 (4)
Methadone, buprenorphine, and
dihydrocodeine
208 (4)
No of treatment episodes:
1 2509 (45)
2 1261 (23)
3 693 (12)
4 457 (8)
5-9 565 (10)
≥10 92 (2)
Episodes (n=13 593)
Comorbidity score†:
≤1/month 7781 (57)
>1/month to ≤1/week 3531 (26)
>1/week 2281 (17)
At least one dose on/above recommended
threshold‡
3261/13 118 (25)
Last dose ≤10 mg methadone 709/7064 (10)
Last dose ≤4 mg buprenorphine 607/1332 (46)
Length of treatment episodes:
Median 70 days
Range 1 day to 15.9 years
Mean (SD) 240 (440) days
*Unless otherwise specified.
†As measured by number of non-opiate substitution prescriptions
received by patient in calendar year.
‡60 mg for methadone, 12 mg for buprenorphine, and 600 mg for
dihydrocodeine.
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episode andwhether the treatment episode included at
least one dose on or above the recommended mainte-
nance thresholds.
After the first four weeks of treatment, the mortality
rate for the rest of time on treatment was 0.6 per 100
person years (table 2). Themortality rate was raised in
the first four weeks: 1.7 per 100 person years in the first
two weeks and 1.3 per 100 person years in weeks three
to four, which after adjustment was 3.1 (1.5 to 6.6) and
2.4 (0.95 to 6.0) times higher than the mortality in the
rest of timeon treatment.Mortalitywas also raised sub-
stantially in the period immediately after treatment, at
4.8 per 100 person years in the first two weeks and 4.3
per 100 person years in weeks three to four, falling
thereafter to just under 1 per 100 person years. After
adjustment, mortality was more than eight times
higher in the first month after treatment stopped and
almost twice as high in the remainder of time off treat-
ment compared with the rate during the stable period
(from onemonth onwards) on treatment. The adjusted
death rate in the first month after treatment stopped
was more than four times higher (mortality rate ratio
4.20, 2.53 to 6.96) than in the subsequent period off
treatment.
Sensitivity and secondary analyses
We found no difference in the risk of death immedi-
ately after treatment between treatment episodes with
and without evidence of tapered prescribing (that is,
planned discharge). The mortality rate ratios in first
28 days off treatment were 8.75 (2.34 to 32.75) with
evidence of tapered prescribing and 8.27 (4.78 to
14.30) without such evidence (interaction test:
χ2=0.32, df=2, P=0.9).
Table 2 | Crude mortalities and mortality rate ratios for all cause mortality
Variable Deaths Person years
Mortality/100
person years
Crude analysis Adjusted analysis*
Mortality rate ratio
(95% CI) P value
Mortality rate ratio
(95% CI) P value
Overall on treatment 62 8939.7 0.69 1.00
<0.001
1.00
<0.001
Overall off treatment 116 8791.8 1.32 1.90 (1.40 to 2.59) 2.29 (1.67 to 3.14)
Period:
Weeks 1-2 of treatment 8 471.5 1.70 2.80 (1.33 to 5.91)
<0.001
3.11 (1.47 to 6.59)
<0.001
Weeks 3-4 of treatment 5 378.7 1.32 2.18 (0.87 to 5.47) 2.38 (0.95 to 5.99)
Remainder of time on treatment 49 8089.4 0.61 1.00 1.00
Weeks 1-2 off treatment 22 458.0 4.80 7.93 (4.80 to 13.12) 9.01 (5.43 to 14.90)
Weeks 3-4 off treatment 19 446.6 4.25 7.02 (4.11 to 11.93) 8.01 (4.70 to 13.66)
Remainder of time off treatment 75 7887.2 0.95 1.57 (1.10 to 2.25) 1.91 (1.32 to 2.76)
Sex:
Female 36 5270.2 0.68 1.00
0.004
1.00
<0.001
Male 142 12 461.2 1.14 1.67 (1.16 to 2.40) 1.97 (1.36 to 2.85)
Age (years):
<30 53 7158.0 0.74 1.00
<0.001
1.00
<0.001
30-39 64 7187.5 0.89 1.20 (0.84 to 1.73) 1.24 (0.86 to 1.79)
40-49 37 2650.3 1.40 1.89 (1.24 to 2.87) 1.85 (1.20 to 2.85)
≥50 24 735.6 3.26 4.41 (2.72 to 7.14) 4.12 (2.47 to 6.86)
Calendar year:
1990-4 23 1326.4 1.73 1.00
0.05
1.00
0.1
1995-9 52 4806.5 1.08 0.70 (0.38 to 1.02) 0.65 (0.40 to 1.06)
2000-4 75 8405.7 0.89 0.56 (0.32 to 0.82) 0.54 (0.34 to 0.87)
2005-6 28 3192.9 0.88 0.56 (0.29 to 0.88) 0.54 (0.31 to 0.95)
Comorbidity score†:
≤1/month 70 10 003.8 0.70 1.00
<0.001
1.00
<0.001>1/month to ≤1/week 56 4630.9 1.21 1.73 (1.22 to 2.46) 1.78 (1.24 to 2.55)
>1/week 52 3096.7 1.68 2.40 (1.68 to 3.44) 2.37 (1.61 to 3.48)
Treatment episode:
First 80 7925.9 1.01 1.00
0.7 Not included
Second 35 4086.6 0.86 0.85 (0.57 to 1.26)
Third or fourth 39 3577.8 1.09 1.08 (0.74 to 1.58)
Fifth or above 24 2141.2 1.12 1.11 (0.70 to 1.75)
At least one dose on/above threshold‡:
No 115 11 546.9 1.00 1.00
0.7 Not included
Yes 53 5646.7 0.94 0.94 (0.68 to 1.30)
*Adjusted for all other variables included in table apart from treatment episode; adjusted rate ratios for variables other than treatment are from model with treatment divided into specific
periods.
†As measured by number of non-opiate substitution prescriptions received by patient in calendar year.
‡Daily dose missing for 475 treatment episodes.
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We foundno evidence of any difference in the risk of
death between buprenorphine and methadone when
we compared the whole period on and off treatment
(table 3). However, we found a few differences in the
crude mortality rates at different periods on and off
treatment between methadone and buprenorphine
but no or weak evidence of an interaction (χ2=7.2,
df=3, P=0.06) (table 3). Specifically, we found no evi-
dence that the risk of death in the first 28 days onor first
28 days off treatment differed betweenmethadone and
buprenorphine. For example, the adjusted mortality
rate ratio was 2.8 (1.1 to 7.0) and 2.5 (0.3 to 18.5) for
the first 28 days on methadone or buprenorphine and
9.5 (5.1 to 17.5) and 15.7 (6.7 to 36.9) for the first
28 days off methadone or buprenorphine, compared
with the risk of death on methadone after the first
28 days of treatment.
Restricting the analysis to the last treatment episode
for each patient (where the date of last treatment was
clear) gave similar results to those in table 2 (see web
appendix table A). Excluding patients who had ever
had a prescription for dihydrocodeine (n=1480
patients) did not alter the overall findings (web appen-
dix table B).
Figure 1 shows the adjusted mortality rate ratios at
different critical periods during and immediately after
treatment compared with the general mortality when
out of treatment. Figure 2 compares the average risk of
death while on opiate substitution treatment with that
while not on opiate substitution treatment by duration
of treatment. Figure 3 estimates the probability that
opiate substitution treatment may reduce overall mor-
tality among the opiate dependent population for dif-
ferent average durations of treatment. Given the
differential mortality rates shown in fig 1, treatment
of comparatively short duration (20 or 30 weeks)
seems not to reduce the overall risk of death (less
than 25% chance; see fig 2 and fig 3). At an average of
40 weeks’ duration of treatment, the chance that treat-
ment reduces overall mortality was 65%; at longer
treatment durations approaching or exceeding a year,
opiate substitution treatment is highly likely (more
than 85% chance) to reduce the overall mortality in
opiate users and lead to a decline in the number of
drug related deaths.
DISCUSSION
Comparedwith the general population, opiate users in
this study had a substantially higher risk of death. The
overall risk of death during opiate substitution treat-
ment was lower than the risk of death out of treatment.
Patients started on opiate substitution treatment had a
twofold to threefold higher risk of death in the first 14
and28days of treatment comparedwith the risk during
the rest of their time on treatment. The risk of death
increased eightfold to ninefold in the month immedi-
ately after the end of opiate substitution treatment.We
found no strong evidence that these effects varied
according to the type of treatment (methadone or
buprenorphine), whether the dose was within recom-
mended treatment thresholds, or whether cessation of
treatment seemed to have been planned (evidence of a
reduced dose before cessation) or unplanned. We
hypothesise that the net benefit of opiate substitution
treatment on overall mortality may relate to the aver-
age duration of treatment.
Table 3 | Mortalities and rate ratios in different periods on/off treatment for buprenorphine and methadone separately
(excluding periods when patient switched during first 28 days of treatment)
Drug Period Deaths Person years
Mortality/100
person years
Adjusted mortality rate ratio
(95% CI)
Methadone
Days 1-28 on treatment 7 464.5 1.51 2.84 (1.14 to 7.04)
Remainder on treatment 23 4664.0 0.49 1.00
Days 1-28 off treatment 21 479.0 4.38 9.47 (5.13 to 17.47)
Remainder off treatment 50 3809.2 1.31 2.99 (1.78 to 5.04)
Buprenorphine
Days 1-28 on treatment 1 80.5 1.24 2.49 (0.33 to 18.51)
Remainder on treatment 6 659.2 0.91 1.64 (0.65 to 4.09)
Days 1-28 off treatment 7 87.5 8.00 15.68 (6.66 to 36.92)
Remainder off treatment 3 663.1 0.45 0.96 (0.29 to 3.23)
Methadone
Overall on treatment 30 5128.5 058 1.00
Overall off treatment 71 4288.2 1.66 3.27 (2.08 to 5.14)
Buprenorphine
Overall on treatment 7 739.7 0.95 1.49 (0.64 to 3.45)
Overall off treatment 10 750.6 1.33 2.45 (1.18 to 5.07)
Interaction tests: for treatment classified as on/off χ2=1.5, df=1, P=0.2; for treatment classified into above periods χ2=7.2, df=3, P=0.06.
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Fig 1 | Adjusted risk of death, compared with not being on
treatment, during and after opiate substitution treatment
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Strengths and weaknesses
Previous large scale studies of drug relatedmortality in
the UK have not investigated the effect of opiate sub-
stitution treatment.31 32 The General Practice Research
Database covers approximately 5% of the population
in general practice and provides a large, reasonably
representative sample of patients taking opiate substi-
tution treatment. Large scale observational studies are
needed because although the risk of death in the first
four weeks of starting or stopping treatment is com-
paratively high, it is transient and unlikely to be
detected in any general practice or even specialist
drug clinic or by any randomised controlled trial. For
instance, the mortality in the first four weeks of opiate
substitution treatment was equivalent to 1 per 1000
treatments, which no general practice and very few
specialist drug clinics will achieve in one year (and no
trials in this area are likely to have sufficient power to
detect differences in such an outcome).
Our study has several weaknesses and potential
biases. Firstly, classification of time on and off treat-
ment was complicated by occasional gaps in the infor-
mation on doses, duration, or quantity prescribed,
which may have led to an underestimate or overesti-
mate of the mortality on or off treatment and therefore
have diluted or exaggerated the difference between
them. However, the findings were similar in a partial
sensitivity test in which we restricted the analysis to the
last treatment episode, and the data are consistent with
other studies.19 24 27
Secondly, patients who transferred out of the data-
base (which in our study was about 10% per year) had
no active follow-up, and patients’ opiate use after leav-
ing opiate substitution treatment was not followed up.
Differences existed in the characteristics of patients
who transferred and those who completed follow-up.
We assumed, therefore, that the mortality of patients
who transferred was the same as for those who
remained in their practice, given adjustment for the
characteristics that were recorded.However, other fac-
tors or unrecorded confounders may be associated
with both mortality and transferring from the study
practice (loss to follow-up) that could be a source of
bias. In addition, some patients who left treatment
will have stopped their opiate use (and therefore have
been at substantially less risk of death than were
patients who relapsed). For this reason, we restricted
follow-up to 12months after treatment, as anymisclas-
sification of patients (and person years) at risk is likely
to be small because the rate of cessation/long term
abstinence is low3334; however, this bias may contri-
bute to a dilution in the risk ratio ofmortality for opiate
users in and out of treatment.
Thirdly, we had limited covariates for which we
could adjust the analyses. For example, we adjusted
for an index of comorbidity, but it was not an ideal
measure and it was not specific to opiate users.29
More importantly, we had no factors that could mea-
sure the quality or intensity of the intervention, which
may have a bearing on both the risk of death at starting
opiate substitution treatment and the likelihood of
relapse and death in the period immediately after
treatment.26 35
Fourthly, the outcome of our study was all cause
mortality, as we had no information on specific causes
of death. Although previous studies in the UK have
shown that most deaths among active opiate users
will be due to overdose, some studies have shown a
greater difference in the risk of overdose during and
after treatment than for all cause mortality, which we
would not have detected.2 27
Finally, our comparisons of the risk of death in
exposed and unexposed populations by duration of
opiate substitution treatment are calculated effects
and not directly observed effects. Themodel estimates
should be taken as evidence to inform (rather than test)
our hypothesis, especially given the limited number of
confounders and that these were secondary analyses.
Nevertheless, no trial is likely to have sufficient power
to measure the effect of duration of opiate substitution
treatment on overall risk of death, so future analyses
must inevitably bederived fromobservational cohorts.
Findings in relation to other studies
The overall risk of death, standardisedmortality ratios,
and overall difference in mortality between time on
and off treatment for opiate users in UK primary care
in this study are consistent with international
literature.436 As previously found in the UK, the risk
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Fig 2 | Comparison of risk of death in patients exposed or not
exposed to opiate substitution treatment (OST) by duration of
treatment. Boxes are interquartile ranges (with median); lines
are 95% confidence intervals
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of death was higher among men using opiates than in
women, which is primarily because men have a higher
risk of overdose than do women; it also means that, as
mortality among young adultmen in the general popu-
lation is higher than in women, the standardised mor-
tality ratios for men and women using opiates were
similar.37 Some other countries with higher rates of
infection related deaths have a similar crude mortality
rate in men and women using opiates and therefore a
higher standardised mortality ratio in women.2 4
The difference in mortality between opiate users in
and out of treatment is stark andwell known, but fewer
studies have investigated the risk of death at the start of
or immediately after treatment.13 19 25 35 Studies in Aus-
tralia and Holland also report a twofold risk in the first
month of treatment23 24; the study in Australia showed
that these deaths were primarily due to overdose and
other injury.24 In contrast, we found a substantially lar-
ger difference inmortality in the first month after treat-
ment stopped than did either the study in Australia
(mortality rate ratio approximately 3) or the one in
Holland (mortality rate ratio approximately 1). Our
findings were similar to those of a study in Italy,
which reported a 10-fold higher risk of overdose in
the first month after treatment stopped compared
with the risk during treatment.27 Furthermore, the four-
fold difference in mortality between the first month
after the end of treatment and the rest of the time off
treatment is similar to the excess riskof death in the first
four weeks after release from prison in the UK com-
pared with the risk of death during the rest of the year
after prison.38 Long term follow-up of injecting drug
users from a single primary care centre suggests that
survival is substantially improved with each year of
exposure to opiate substitution treatment,34 as we esti-
mate in figure 2. In addition,McCowan and colleagues
showed that overall survival was unrelated to recom-
mended levels of methadone prescription.39
Implications for policy and practice
Our study could not test mechanisms, so any inference
in this regardmust be cautious.However,weknow that
death fromoverdose of opiates is caused by respiratory
depression, that the risk of overdose is increased at
times when tolerance of opiate has temporarily fallen
after voluntary or involuntary reductions in use,40 and
that relapse rates after treatment or abstinence from
opiate use are high.15 41 Therefore, the first few
occasions of opiate use pose the greatest risk of preci-
pitating fatal overdose before tolerance has been
re-established. Induction on to opiate substitution
treatment, especially with methadone, also poses
risks in terms of overdose if the initial dose is too high
or if patients continue to use non-prescribed opiates,
and the change may be a cause of mental distress.24 26
Closer supervision of induction of treatment alongside
the development ofmore effectivemethods of prevent-
ing relapse may mitigate these effects, and further
research should consider these questions. The identifi-
cation and evaluation of better management and prac-
tice of opiate substitution treatment will be complex
and require large scale studies. Ongoing monitoring
of the impact of opiate substitution treatment on mor-
tality in the UK and other countries is warranted, par-
ticularly investigation of specific causes of death. As
most trials are severely underpowered to investigate
risk of death, establishing the extent to which time to
“relapse” or frequency of use can be a surrogate out-
comeor biomarker ofmortalitywill be very important.
Finally, provision of opiate substitution treatment
has substantially increased in the UK,7 but the total
number of deaths due to overdose of opiates has
remained stable and national targets to reduce their
number have not been met.6 We hypothesise that the
raised risk of death in the first month of treatment and
especially in the month after the end of treatment may
negate any protective effect of opiate substitution treat-
ment, unless treatment is prolonged. In our study, the
mean duration of treatment was 34 weeks which, as
figure 3 suggests, may not necessarily lead to a decline
in the overall number of deaths. Further research is
needed to test this hypothesis and investigate the effect
of average duration of opiate substitution treatment on
drug related mortality.
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